Correspondence 0001213900-24-109875 from Estrella Immunopharma, Inc. (ESLA, ESLAW) (CIK 0001844417) (ESLA)
Estrella Immunopharma, Inc. (ESLA, ESLAW) (CIK 0001844417)
Date: Dec. 17, 2024 · CIK: 0001844417 · Accession: 0001213900-24-109875
AI Filing Summary & Sentiment
File numbers found in text: 333-283770
Letter
Re: Estrella Immunopharma, Inc.
December 17, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-3
File No. 333-283770
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Estrella Immunopharma, Inc., a Delaware corporation (the “Company”), hereby requests that the effective date of the above referenced Registration Statement on Form S-3 (the “Registration Statement”), be accelerated so that the same will become effective at 4:00 p.m., Eastern Time, on Thursday, December 19, 2024, or as soon as practicable thereafter.
Please notify Michael Blankenship of Winston & Strawn LLP, counsel to the Company, at (713) 651-2678 or at MBlankenship@winston.com, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.
Very truly yours,
Estrella Immunopharma, Inc.
Show Raw Text
CORRESP
1
filename1.htm
December 17, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re:
Estrella Immunopharma, Inc.
Registration Statement on Form S-3
File No. 333-283770
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities
Act of 1933, as amended, Estrella Immunopharma, Inc., a Delaware corporation (the “Company”), hereby requests
that the effective date of the above referenced Registration Statement on Form S-3 (the “Registration Statement”),
be accelerated so that the same will become effective at 4:00 p.m., Eastern Time, on Thursday, December 19, 2024, or as soon as practicable
thereafter.
Please notify Michael Blankenship of Winston &
Strawn LLP, counsel to the Company, at (713) 651-2678 or at MBlankenship@winston.com, as soon as the Registration Statement has been
declared effective, or if you have any other questions or concerns regarding this matter.
Very truly yours,
Estrella Immunopharma, Inc.
By:
/s/ Cheng Liu
Name:
Cheng Liu
Title:
Chief Executive Officer
cc: Michael Blankenship, Esq.